![]() |
Volumn 53, Issue 7, 2013, Pages 721-730
|
Population pharmacokinetic analysis of orally-administered ruxolitinib (incb018424 phosphate) in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)
|
Author keywords
Myelofibrosis; Population pharmacokinetics; Ruxolitinib
|
Indexed keywords
ALBUMIN;
DIGOXIN;
PLACEBO;
PREDNISONE;
RUXOLITINIB;
WARFARIN;
ACCURACY;
ADULT;
AGED;
ALBUMIN BLOOD LEVEL;
ANALYTICAL ERROR;
ARTICLE;
BODY WEIGHT;
COMPARTMENT MODEL;
DRUG ABSORPTION;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG ELIMINATION;
FEMALE;
GENDER;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MYELOFIBROSIS;
MYELOID METAPLASIA;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
POLYCYTHEMIA VERA;
POPULATION MODEL;
POST-ESSENTIAL THROMBOCYTOPENIA MYELOFIBROSIS;
POSTPOLYCYTHEMIA VERA MYELOFIBROSIS;
PREDICTIVE VALUE;
THROMBOCYTHEMIA;
AGED;
CLINICAL TRIALS, PHASE III AS TOPIC;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
JANUS KINASES;
MALE;
MODELS, BIOLOGICAL;
POLYCYTHEMIA VERA;
PRIMARY MYELOFIBROSIS;
PROTEIN KINASE INHIBITORS;
PYRAZOLES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
THROMBOCYTHEMIA, ESSENTIAL;
|
EID: 84880321287
PISSN: 00912700
EISSN: 15524604
Source Type: Journal
DOI: 10.1002/jcph.102 Document Type: Article |
Times cited : (32)
|
References (8)
|